Months before Tamil Nadu goes to polls, the state is set to get an infrastructure bonanza, with the Chennai Metro Rail Corporation Ltd (CMRL) floating a series of bids this week to start the process ...

The draft of electric vehicle (EV) policy 2.0, which is likely to be announced soon by the Delhi government, recommends the phasing out of CNG-driven auto rickshaws, officials said on Monday.

There are two types of bipolar disorder bipolar 1 disorder and bipolar 2 disorder. Bipolar 1 disorder is characterized by moods vacillating between depression and mania. With bipolar 2 disorder, moods ...

The registration deadline for Round 2 of the Prime Minister Internship Scheme 2025 has been extended to April 15, giving students and young professionals more time to apply. The scheme offers year ...

Racing toward a $1.6 billion market, the biotech stopped work on RLYB212 in a rare maternal immune disorder in response to phase 2 data. RLYB212, an anti-HPA-1a antibody, was in phase 2 ...

The Space Force anticipates assigning 54 missions under NSSL Phase 3 Lane 2 in fiscal 2025-29. The service has earmarked seven of those missions for Blue Origin, which would involve “less ...

In two phase 3, double-blind, double-dummy, event-driven trials (GEMINI 1 and GEMINI 2), participants with relapsing multiple sclerosis were randomly assigned in a 1:1 ratio to receive ...

Etihad Rail is moving construction ahead at an accelerated pace with 75% of the 1200km Phase 2 of the UAE’s national railway network now complete. Deputy executive director of projects, Mohammed ...

Phase 4 saw TV shows folded into the MCU's interconnected storylines more than ever before and this has continued throughout Phase 5 and the already-confirmed Phase 6, which will wrap up with an ...

The Nintendo Switch 2 is real and it's launching in June! After literal years of unverified rumors, dubious leaks and copious amounts of online speculation, Nintendo has lifted the lid on its next ...

AC Immune SA AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active immunotherapy with ACI-7104.056 ...

ORLANDO, Fla. — A second phase 2 trial with the tyrosine kinase 2 (TYK2) inhibitor deucravacitinib has met the primary efficacy endpoints for the treatment of the skin manifestations of ...